Abstract:Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer (NK) cells are emerging tools for cancer therapy. However, only subpopulations of NK cells that are differentially controlled by inhibitory receptors exert reactivity against particular cancer types. How to leverage the complete anti-tumor potential of all NK cell subsets without favoring the emergence of NK cell-resistant tumor cells remains unresolved. Methods We performed a genome-wide CRISPR/Cas9 knockout resistance screen in melanoma cells in co-cultures with human primary NK cells. We comprehensively evaluated factors regulating tumor resistance and susceptibility by focusing on NK cell subsets in an allogenic setting. Moreover, we tested therapeutic blocking antibodies currently used in clinical trials. Results Melanoma cells deficient in antigen-presenting or the IFNγ-signaling pathways were depleted in remaining NK cell-co-cultured melanoma cells and displayed enhanced sensitivity to NK cells. Treatment with IFNγ induced potent resistance of melanoma cells to resting, IL-2-cultured and ADCC-activated NK cells that depended on B2M required for the expression of both classical and non-classical MHC-I. IFNγ-induced expression of HLA-E mediated the resistance of melanoma cells to the NKG2A + KIR − and partially to the NKG2A + KIR + NK cell subset. The expression of classical MHC-I by itself was sufficient for the inhibition of the NKG2A − KIR + , but not the NKG2A + KIR + NK cell subset. Treatment of NK cells with monalizumab, an NKG2A blocking mAb, enhanced the reactivity of a corresponding subset of NK cells. The combination of monalizumab with lirilumab, blocking KIR2 receptors, together with DX9, blocking KIR3DL1, was required to restore cytotoxicity of all NK cell subsets against IFNγ-induced resistant tumor cells in melanoma and tumors of different origins. Conclusion Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.

Global inhibition of the interaction of NK inhibitory receptors with MHC-I augments coordinated innate and adaptive immunity against cancer metastasis.

Expansion of NK Cells by Engineered K562 Cells Co-Expressing 4-1BBL and Mmica, Combined with Soluble IL-21.

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

Tumor MHC Class I Expression Alters Cancer-Associated Myelopoiesis Driven by Host NK Cells.

Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms

Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?

MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides

Natural killer cells in cancer immunotherapy

Data from Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity Against Tumors Resistant to Cytotoxic T Cells

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

Killer Immunoglobulin-Like Receptors/human Leukocyte Antigen Class-I, a Crucial Immune Pathway in Cancer

Natural killer (NK) cell high-mobility group box 1 (HMGB1) is required for anti-tumor function (TUM2P.895)

MHC-I Molecules Selectively Inhibit Cell-Mediated Cytotoxicity Triggered by ITAM-Coupled Activating Receptors and 2B4

Opposing Effects of Interferon-Alpha and Interferon-Gamma on the Expression of Major Histocompatibility Complex Class I Chain-Related A in Tumors.

Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

Natural killer group 2D‐major histocompatibility complex class I polypeptide‐related sequence A activation enhances natural killer cell‐mediated immunity against hepatocellular carcinoma: A review